Gastroenterology · USMLE Step 1 and Step 2

Proton Pump Inhibitors song

Proton Pump Inhibitors - Mechanism & Risks, as a song. Hear the short teaser here. The full song is on YouTube and Spotify.

Proton Pump Inhibitors

Full song on YouTube ↗Spotify ↗

Key points in this song10

PPIs irreversibly inhibit the H⁺/K⁺-ATPase (proton pump) on the parietal cell, providing the most potent acid suppression of any drug class.
PPIs are prodrugs activated in the acidic canaliculus of the parietal cell; they must be taken 30–60 minutes before meals for maximal efficacy.
First-line treatment for GERD, peptic ulcer disease, Zollinger-Ellison syndrome, and as part of H. pylori eradication regimens (PPI + clarithromycin + amoxicillin).
Zollinger-Ellison syndrome (gastrinoma) requires high-dose PPI therapy; serum gastrin levels are markedly elevated (>1000 pg/mL is classic).
Long-term PPI use causes hypergastrinemia due to loss of acid-mediated negative feedback, leading to parietal cell and enterochromaffin-like (ECL) cell hyperplasia.
Chronic PPI use is associated with hypomagnesemia, hypocalcemia, and increased risk of osteoporotic fractures due to impaired acid-dependent mineral absorption.
PPIs increase risk of Clostridioides difficile infection and community-acquired pneumonia by reducing the bactericidal effect of gastric acid.
PPIs inhibit CYP2C19, reducing activation of clopidogrel (a prodrug), potentially increasing cardiovascular event risk when co-administered.
Long-term PPI use is associated with vitamin B12 deficiency because gastric acid is required for cleavage of B12 from dietary protein.
Rebound acid hypersecretion occurs upon abrupt PPI discontinuation due to upregulated proton pumps, necessitating gradual tapering after prolonged use.